Northwest Biotherapeutics, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $3.0M | $2.2M | $2.1M | $7.0M | $15.2M | $10.0M | $372.0K | $22.2M |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $5.5M | $4.1M | $4.1M | $9.4M | $17.3M | $15.5M | $3.2M | $23.8M |
| Property, Plant & Equipment | $17.4M | $16.2M | $17.3M | $13.4M | $15.0M | $1.0M | $281.0K | $108.0K |
| Goodwill | $626.0K | $626.0K | $626.0K | $626.0K | $626.0K | $626.0K | $0 | — |
| Intangible Assets (Excl. Goodwill) | $53.2M | $1.3M | — | — | — | — | — | — |
| Total Assets | $81.3M | $26.7M | $27.9M | $31.3M | $40.2M | $32.9M | $10.6M | $24.7M |
| Liabilities | ||||||||
| Accounts Payable | $30.8M | $17.0M | $10.2M | $10.7M | $7.0M | $7.4M | $6.3M | $15.5M |
| Total Current Liabilities | $91.7M | $68.3M | $45.2M | $126.0M | $133.8M | $382.4M | $44.2M | $69.8M |
| Long-Term Debt | $60.0M | $62.7M | $40.8M | $21.5M | $32.4M | $14.8M | $12.7M | $16.8M |
| Total Liabilities | $128.9M | $105.7M | $74.9M | $136.4M | $164.2M | $395.8M | $55.7M | $71.8M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-1.50B | $-1.44B | $-1.36B | $-1.30B | $-1.19B | $-1.37B | $-841.4M | $-824.4M |
| Total Stockholders' Equity | $-60.3M | $-94.5M | $-65.8M | $-128.1M | $-124.0M | $-362.9M | $-45.1M | $-48.1M |